TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Analgesia and Physiotherapy in Children With Cerebral Palsy (ANTALKINECP)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Cerebral palsy hemiplegic diplegic or tetraplegic spastic or not.~* Children who feel pain during the pre-screening physiotherapy session with a VAS score above 2.~* Aged 6 to 17 years of both gender.~* Ability to express his/her pain and to measure its intensity with VAS.~* Informed and signed (parents, investigator and child if possible).~Exclusion Criteria:~* Lack of physiotherapy.~* Analgesic treatment already available or stopped in the last month.~* Scheduled surgery procedure or botulinum toxin injection during the period of the assessment of pain (around 5 month)~* The last botulinum toxin injection in two months before the inclusion~* Child who feel pain with EVA score superior or equal to 4 at the time of the inclusion outside the sessions of physiotherapy~* Child unable to cooperate.~* Severe infection or instable vital functions.~* Hypersensitivity to ibuprofen or any of the constituents in the product.~* History of allergy or asthma triggered by taking ibuprofen or substances of near activity such as other NSAIDs and aspirin.~* Allergy to other component of treatment.~* History of upper gastrointestinal bleeding or perforation, related to previous NSAID therapy.~* Active gastrointestinal ulcer.~* Severe hepatic failure.~* Severe renal failure.~* Uncontrolled severe cardiac failure.~* Systemic Lupus Erythematosus.~* Regular intake of ibuprofen~Randomisation Criteria:~• Child who feel pain during the physiotherapy session with a mean VAS score above 3 during the screening phase.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Ibuprofen (Type: EXPERIMENTAL): Active ibuprofen
- Placebo (Type: PLACEBO_COMPARATOR): Placebo of ibuprofen

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Proprioceptive Focal Stimulation (EQUISTASI) on Freezing of Gait in Parkinson's Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patient with Parkinson's Disease~* Stable drug therapy response without any change in the 3 months before the study.~* written informed consent~Exclusion Criteria:~* Hoehn-Yahr stage ≥ 4~* Cognitive decline (Mini Mental State Examination \<26)~* Systemic illness involving the nervous system~* Diabetes~* Presence of cardiac pacemaker~* Presence of deep brain stimulation~* Presence of severe dysautonomia with marked hypotension~* History or active neoplasia~* Pregnancy

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- EQUISTASI (Type: EXPERIMENTAL): Equistasi is a nanotechnology for proprioceptive focal stimulation. Every patient will receive four patches to be placed on both legs for 4 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Lactobacillus Reuteri in Premature Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Preterm newborns admitted to the neonatal intensive care units with a birth weight 700-1500 g and who survive more than 3 days~Exclusion Criteria:~* Chromosomal anomalies.~* Major congenital anomalies (complex cardiac anomalies, congenital hydrocephalus, renal dysplasia)~* Congenital (e.g. jejunal atresia) and acquired (e.g. GI perforation) gastrointestinal pathology precluding oral feed and/or requiring major surgical or medical intervention~* Parental refusal~* Prior enrollment into a conflicting clinical trial

- Gender: ALL
- Minimum Age: None
- Maximum Age: 6 Months
- Healthy Volunteers: f

Study Arms:
- probiotic group (Type: EXPERIMENTAL): Lactobacillus reuteri will be given at a dose of 1x108 colony forming units (CFU)/day
- Placebo (Type: PLACEBO_COMPARATOR): The placebo consists of an identical formulation except that the L. reuteri is not present.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Prunes for Gastrointestinal Function After Gynecologic Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Female patients seen in the Gynecology or Urogynecology clinics at LAC+USC Medical Center who are planned for surgery requiring at least 24 hour stay~2. Age 18 or greater~3. Able to give informed consent~4. No contraindications to docusate or prune consumption~Exclusion Criteria:~1. Unable to give informed consent~2. Unwilling to follow protocol~3. Active malignancy~4. Emergency surgery~5. Diabetes mellitus~6. Inflammatory bowel disease, gastroparesis, or other bowel disorder~7. History of bowel resection or presence of colostomy~8. Dependence on regular laxative use prior to surgery~9. Baseline frequency of bowel movements less than weekly~10. Intraoperative enterotomy or any bowel surgery performed at the time of surgery~11. Patient unable to initiate oral intake on post op day 1 for any reason~12. Allergy to docusate or prunes

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Prunes (Type: EXPERIMENTAL): The study group will be instructed to consume 4 oz of prunes as well as docusate sodium twice daily for 3 days after surgery.
- Control (Type: PLACEBO_COMPARATOR): The placebo group will be instructed to take docusate sodium twice daily for 3 days after surgery.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Ethiopia Group Antenatal Care Study at the Health Post Level

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Minimum age of 15 years at the time of enrollment; pregnant 15-17 year-olds will be treated as emancipated/mature as per local regulations~* Gestational age less than or equal to 20 weeks at the time of enrollment determined by last menstrual period (LMP), pelvic exam, fundal height, quickening, ultrasound, and/or timing of fetal heart tones and pregnancy test~* Pregnant women able and willing to provide adequate locator information~* Planning to reside at their current location for at least 10 months~* Agree to participate in the study and continue ANC at health post~* Willing to participate and consent to follow up for up to 6 weeks post-delivery~* Are willing to receive group antenatal care at the health post level (during the intervention period)~Exclusion Criteria:~* Women who plan to travel away from the study site for more than four consecutive weeks during ANC or after 6 weeks post-delivery~* Women who are unable provide consent~* Women who have any condition that in the opinion of the investigator or designee, would complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives

- Gender: FEMALE
- Minimum Age: 15 Years
- Maximum Age: 49 Years
- Healthy Volunteers: t

Study Arms:
- Group ANC (Type: EXPERIMENTAL): Intervention period in stepped wedge design where women are receiving antenatal care in a group setting
- Individual ANC (routine) (Type: NO_INTERVENTION): Pre-intervention time period (control period) where the intervention is not being implemented yet (women are receiving individual antenatal care as is currently offered)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Collection of Biological Samples With Clinical Characterization of Covid-19 Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of COVID-19 confirmed on RT-PCR test or chest scanner~* Any age~* Membership in the general social security system~* Inform consent signed by the patient or by legal representatives for minors~Exclusion Criteria:~* Refusal of the patient or one of the legal representatives

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Collection of blood sample (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Real World Effectiveness of Eptinezumab in Participants With Migraine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Have a diagnosis of migraine per International Headache Society (IHS) International Classification of Headache Disorder (ICHD)-3 guidelines at least 12 months prior to screening.~* Have a history of ≥ 8 migraine days/month in 2 of the previous 3 months as confirmed by the treating physician through medical records.~* Be able to understand the clinical description of treatment options and have the capability to participate fully in making their treatment preferences known.~* Be willing to accept randomization to any of the possible study medications if allocated to that treatment arm.~* Be willing and capable of completing daily reports and other participant reported outcome measures using a smartphone-based application.~Exclusion Criteria:~* The participant has a history of severe drug allergy or hypersensitivity, or known hypersensitivity or intolerance to either eptinezumab, erenumab, fremanezumab, galcanezumab or their excipients.~* The participant has previous history of use of any of the study drugs (for example, eptinezumab, Botox, erenumab, fremanezumab or galcanezumab). Note that only previous Botox use for treatment of migraine is exclusionary. Prior use of Botox for cosmetic purposes is allowed.~* The participant has a diagnosis of CM and has hypersensitivity to botulinum toxin preparation or to any of the components in the formulation.~* The participant has used opioids or butalbital-containing products greater than 4 days per month in the last month.~Other inclusion and exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Eptinezumab (Type: EXPERIMENTAL): Participants will receive eptinezumab via intravenous (IV) infusion on Day 0 and Day 84.
- Anti-CGRP injectables (Type: EXPERIMENTAL): Participants are free to select treatment from one of 3 calcitonin gene-related peptide (CGRP) inhibitors: erenumab, fremanezumab, or galcanezumab. CGRP inhibitors will be administered via subcutaneous (SC) injection on Day 0 and then, per product label.
- Onabotulinumtoxin-A (Type: EXPERIMENTAL): Onabotulinumtoxin-A will be administered via intramuscular (IM) injection on Day 0 and Day 84.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Comparison of Dexmedetomidine and Midazolam for the Sleep in Intensive Care Unit

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* sedation patients with dexmedetomidine or midazolam~* over 18 years old~Exclusion Criteria:~* Neurologic disease (stroke, seizure, dementia, hypoxic brain damage)~* Brain infection~* Alcoholics~* Major Depression Disorder, Schizophrenia, Anxiety disorder~* Hearing loss

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dexmedetomidine group (Type: None): Dexmedetomidine group is the patients who sedated with dexmedetomidine in intensive care unit. We will randomly allocate using www.randomizer.org.~They will sedate at the level of RASS -2. The dose of dexmedetomidine will be 0.2-0.7ug/kg/hr.
- Midazolam group (Type: None): Midazolam group is the patients who sedated with midazolam in intensive care unit. We will randomly allocate using www.randomizer.org.~They will sedate at the level of RASS -2. The dose of midazolam will be 0.05-0.1 mg/kg/hr.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Tolerability, Safety and Effectiveness of Edratide in the Treatment of Lupus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Willing and able to give written informed consent~2. Between the ages of 18 and 65 years (inclusive)~3. Fulfilled at least 4 ACR classification criteria~4. SLE patients with moderate, active disease~5. Subjects on stable dose of SLE medications for at least 4 weeks before randomization.~6. Women of child-bearing potential must practice a medically acceptable method of contraception..~7. Must understand the requirements of the study and agree to comply with the study protocol.~Exclusion Criteria:~1. Any condition which the investigator feels may interfere with participation in the study.~2. Subjects having a history of chronic infection~3. Subjects with a history of immunodeficiency syndrome or malignancy,~4. Subjects who received any investigational medication (including DHEA) within 3 months prior to randomization,~5. Subjects treated with any cytotoxic agents in the 3 months prior to randomization.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Investigation of the Effects of Electronic Cigarettes on Vascular Health

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female between 18 and 50 years of age.~* Good general health with no history of diabetes, coronary artery disease, peripheral arterial disease, chronic disease or hypertension.~* Ability to sign an informed consent.~Tobacco product users will have additional inclusion criteria:~* For TC smokers, daily TC smoking in the past 6 months, at least 10 cigarettes per day, with no EC exposure in the past 6 months~* For EC users, daily EC use in the past 6 months, at least 10 sessions per day, with no TC exposure in the past 6 month~* For non-smokers, no significant lifetime exposure to any nicotine-containing product, where significant exposure is defined as daily use of any nicotine-containing product for more than one week or once monthly use for more than 6 months.~Exclusion Criteria:~* History of renal disease, hypertension, diabetes, congestive heart failure or emphysema~* Use of ACE inhibitors, Angiotensin II receptor blockers, diuretics, aldosterone, renin blockers, aspirin, statins, sildenafil (or other PDE5 inhibitors) and NSAIDs.~* History of substance abuse~* Currently using nicotine replacement or other tobacco cessation products or intentionally abstaining from nicotine-containing products~* IV contrast exposure in the past 1 month~* Inability to place an IV catheter or draw blood for any reason~* Pregnant women or breastfeeding~  * Potential subjects will be asked if they are pregnant. Verbal confirmation of pregnancy will be sufficient.~* Fever of \>101°F or BP \>180/95~* BMI ≥30

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Electronic cigarettes (EC) smokers (Type: EXPERIMENTAL): None
- traditional cigarette (TC) smokers (Type: EXPERIMENTAL): None
- nonsmokers (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Pneumocystis in COPD (the TOPIC Study)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Carries the diagnosis of COPD and admitted for and admitted with AECOPD to Beaumont, Royal Oak (AECOPD requires increased cough, increased sputum production, and shortness of breath +/- increased oxygen needs from baseline)~* Able to produce a sputum sample~* Men or women, age ≥ 40 and \< 90~* Previously enrolled in the EPIC Study and positive for Pneumocystis jirovecii detected in their sputum~* Currently treated with steroids~* Kidney function not severely impaired (CrCl ≥ 60)~* AST and ALT ≤5x upper limit of normal~* Willing and able to consent to the study~Exclusion Criteria:~* Current diagnosis of pneumonia or COVID-19~* Allergy or hypersensitivity to trimethoprim-sulfamethoxazole~* Current ICU admission or mechanical ventilation~* Active cancer or chemotherapy (except non-melanoma skin cancer)~* Other potentially confounding pulmonary diagnosis~* HIV, leukopenia, neutropenia, or other immunosuppressive condition or current use of immunosuppressive medications~* Presence of gastrointestinal tract abnormalities that would prevent absorption of medications~* Patients with concomitant infection requiring antibiotics active against Pneumocystis jirovecii~* Concomitant use of coumadin, phenytoin, pioglitazone, repaglinide, rosiglitazone, glipizide or glyburide~* Megaloblastic anemia due to folate deficiency~* Pregnancy~* Life expectancy less than 3 months

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 89 Years
- Healthy Volunteers: f

Study Arms:
- TMP-SMX (Type: EXPERIMENTAL): Suspension with the equivalent of one DS TMP-SMX by mouth every 12 hours for 10 days
- Placebo (Type: PLACEBO_COMPARATOR): Suspension with placebo by mouth every 12 hours for 10 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: PTX-200 and Carboplatin in Ovarian Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* At least 18 years of age~* Histologically confirmed, measurable or non-measurable, recurrent or persistent, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal carcinoma. By standard Gynecologic Oncology Group (GOG) criteria, platinum-resistant disease is defined by a disease-free interval of less than 6 months following treatment with a platinum-based regimen, or the progression of disease during platinum-based therapy.~* At least one prior regimen of chemotherapy, with no maximum number of chemotherapy cycles~* A serum creatinine ≤ 1.5 mg% obtained ≤ 2 weeks prior to entry~* Adequate hematologic reserve obtained ≤ 2 weeks prior to entry: leukocytes ≥ 3,000 mm\^3; absolute neutrophil count ≥ 1500 mm\^3; platelets ≥ 100,000 mm\^3~* Adequate hepatocellular function: aspartate aminotransferase (AST) and alanine transaminase (ALT) ≤ 3x upper limit of normal within institutional limits; bilirubin ≤ 1.5 mg/dl~* Gynecologic Oncology Group (GOG) Performance Status of 0, 1, or 2~* Life expectancy of at least 90 days~* The patient should be off chemotherapy, biologic therapy and radiation for 28 days.~* Neuropathy (sensory and motor) less than or equal to grade 1 per Common Toxicity Criteria (CTC) version 4~Exclusion Criteria:~* Prior TCN-PM therapy~* History of allergic reactions attributed to compounds of similar chemical or biologic composition to TCN-PM~* Patients must be disease-free of prior invasive malignancies for \>2 years with the exception of basal cell or squamous cell carcinoma of the skin.~* Inability to give informed consent~* Pregnancy~* Corrected QT interval (QTc) prolongation \> 450 milliseconds (msec)

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Triciribine & Carboplatin (Type: EXPERIMENTAL): Phase I/II: 25mg/m\^2 Triciribine and Carboplatin AUC 4. Triciribine escalated to 30, 35, 45mg/m\^2 if toxicities are not encountered.~Phase II: Recommended phase II dose of triciribine and carboplatin.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues